Lipocine Inc. (NASDAQ:LPCN) shares traded up 1.9% during trading on Friday . The stock traded as high as $3.90 and last traded at $3.77, with a volume of 53,483 shares. The stock had previously closed at $3.70.

Separately, Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price target on shares of Lipocine in a research note on Wednesday, August 10th.

The company has a 50-day moving average of $3.60 and a 200-day moving average of $8.01. The company’s market cap is $67.01 million.

Lipocine (NASDAQ:LPCN) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.05. On average, analysts forecast that Lipocine Inc. will post ($1.31) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Lipocine stock. Dimensional Fund Advisors LP raised its position in Lipocine Inc. (NASDAQ:LPCN) by 73.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 271,272 shares of the specialty pharmaceutical company’s stock after buying an additional 114,448 shares during the period. Dimensional Fund Advisors LP owned approximately 1.49% of Lipocine worth $3,508,000 at the end of the most recent reporting period.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.